Roche
No price chart data available for 1D timeframe.
Rating
Why Price Moved
Shares are trading higher after Roche announced po...
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Roche Holding AG functions as a major global healthcare enterprise, primarily concentrating its efforts within the pharmaceutical and diagnostic sectors. The company boasts an extensive international ...
Latest News
8 hours ago · globenewswire.com
FDA approves Roche's Wilserdly (giredestrant), a next-generation oral SERD, for ER-positive, ESR1-mutated advanced breast cancerBasel, 16 November 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the United States (U.S.) Food and Drug Administration (FDA) has approved Wilserdly™ (giredestrant) in combination with everolimus for the treatment of adults with oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated locally advanced or metastatic breast cancer, as detected by an FDA-authorised test, whose disease has recurred during or after completion of endocrine-based adjuvant therapy, or has progressed on at least one endocrine-based regimen in the metastatic setting.
9 hours ago · reuters.com
US FDA approves Roche's oral treatment for advanced breast cancerUS FDA approves Roche's oral treatment for advanced breast cancer
16 hours ago · prnewswire.com
Roche receives FDA De Novo authorization for cobas® pro i 601 platform with Ionify® Gabapentin assay, advancing automated mass spectrometry for routine clinical laboratoriesFDA De Novo authorization for the cobas® pro i 601 platform with Ionify® Gabapentin assay expands Roche's mass spectrometry menu into therapeutic drug monitoring. Designed to simplify traditionally complex testing, the solution brings the analytical capabilities of mass spectrometry together with an automated, standardized laboratory workflow.
18 hours ago · youtube.com
Chances of Jensen Huang returning to Nvidia 'very slim': David RocheDavid Roche, President and Global Strategist at Quantum Strategy says he's out of the AI trade because it's a bubble and that he "wouldn't touch NVIDIA with a barge pole". He adds Nvidia's growth outlook is also weakening, citing Jensen Huang's role, its Taiwan ties and lost access to China, and expects the shares to settle below current levels.
18 hours ago · businesswire.com
Faeth Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate PIKTOR in Combination with a Selective Estrogen Receptor Degrader in HR+/HER2- Advanced Breast CancerAUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced that it has entered into a clinical trial collaboration and supply agreement with F. Hoffmann-La Roche Ltd (Roche) to evaluate PIKTOR in combination with the investigational medicine giredestrant in patients with hormone receptor-positive, HER2-negative (HR+/HER2-) advanced breast cancer. Under.
6 days ago · businesswire.com
Perficient Expands Its Innovation Center to Advance Roche Diagnostics' Molecular Laboratory SystemsCLUJ-NAPOCA, Romania--(BUSINESS WIRE)--Perficient, in collaboration with Roche Diagnostics, announced the expansion of its dedicated innovation center in Cluj-Napoca, Romania.
15 days ago · prnewswire.com
Roche receives FDA 510(k) clearance for new cobas® eplex respiratory pathogen panel 3, enabling labs to customize respiratory testing for local patient needsThe new cobas ® eplex RP3 panel detects up to 19 viruses and bacteria, with newly added Bordetella pertussis and improved inclusivity of influenza A and SARS-CoV-2 strains, from a single sample to inform timely patient management. Laboratories can optimize resources with up to five flexible panel configurations tailored to local disease prevalence and patient needs, enabled by cobas® eplex system software version 3.0 or higher.
19 days ago · seekingalpha.com
Roche: Valuation Leaves Limited UpsideRoche delivered 7% Q3 sales growth at constant currency, although approximately CHF 180 million was attributable to shipments that had been brought forward in Japan. Pharmaceuticals performed well, but Chinese pricing reforms continue to weigh on Diagnostics, while FX remains a headwind to reported earnings. Giredestrant and fenebrutinib offer future growth opportunities, although regulatory approvals and commercial performance remain important uncertainties.
21 days ago · globenewswire.com
Roche receives CE Mark for cobas® smart e immunoanalyser, completing a portfolio that brings central-lab precision to healthcare settings ranging from small clinics to large hospital laboratoriesThe cobas smart e immunoanalyser - the newest addition to Roche's industry-leading cobas immunoassay systems portfolio - is engineered to deliver central-lab performance in a footprint under one square metre. With a planned menu of over 100 high-medical-value assays, and reaction times of 18 minutes or less for more than 90% of tests, the platform allows smaller laboratories to bring testing in-house, reducing turnaround times for patients.
22 days ago · globenewswire.com
Billions in New Plants, Trillions in Potential Obesity-Drug Revenue Over Two DecadesDENVER, Oct. 26, 2026 (GLOBE NEWSWIRE) -- (247marketnews. com) - Eli Lilly (NYSE: LLY), Novo Nordisk (NYSE: NVO), AstraZeneca (NYSE: AZN), and Roche (OTCQX: RHHBY) are among the biopharma companies committing billions of dollars to new manufacturing facilities as obesity medicines become a major commercial opportunity.
Add to Watchlist
Select watchlists to add or remove RHHBY